Macrophage activation syndrome: a lifetrheatening complication in a 44 year old woman

Published: 20 June 2024
Abstract Views: 64
PDF: 41
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Macrophage activation syndrome (MAS) is a potentially life-threatening complication of autoimmune diseases. A 44-yearold woman was admitted to the hospital for further evaluation due to swelling in the left latero-cervical region, a mild fever that persisted for two weeks, itchy papular skin lesions, oral ulcers, and diffuse joint pain. Her medical history reported hypertension, diffused painful joints, and a pauci-symptomatic recent SARS-CoV-2 infection. A severe, drug-resistant fever developed while the patient was in the hospital. Infectious diseases were excluded and blood cultures, swabs, and serum antibody dosages were carried out. In a patient with systemic lupus erythematosus, MAS was diagnosed due to the presence of fever, bilinear cytopenia, high ferritin, transaminase, and triglyceride levels with low fibrinogen levels. Methyl-prednisolone at immunosuppressive dosages and cyclosporine were started. Hematobiochemical parameters gradually returned to normal as the fever subsided. The patient’s condition is being monitored while the cyclosporine therapy is continued and the steroidal therapy is gradually tapered off. It was not possible to show a potential link to the SARS-CoV-2 infection.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Ravelli A, Davì S, Minoia F, et al. Macrophage activation syndrome. Hematol Oncol Clin North Am 2015;29:927-41. DOI: https://doi.org/10.1016/j.hoc.2015.06.010
Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012;13:289-98. DOI: https://doi.org/10.1038/gene.2012.3
Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 2016;12:259-68. DOI: https://doi.org/10.1038/nrrheum.2015.179
Vilaiyuk S, Sirachainan N, Wanitkun S, et al. Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review. Clin Rheumatol 2013;32:899-904. DOI: https://doi.org/10.1007/s10067-013-2227-1
Borgia RE, Gerstein M, Levy DM, et al. Features, treatment, and outcomes of macrophage activation syndrome in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 2018;70:616-24. DOI: https://doi.org/10.1002/art.40417
Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. Open Access Rheumatol 2018;10:117-28. DOI: https://doi.org/10.2147/OARRR.S151013
2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019;71:1400-12.
Ravelli A, Minoia F, Davì S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 2016;68:566-76. DOI: https://doi.org/10.1002/art.39332

How to Cite

Natale, R., Morena, A., Nasti, C., Bertolini, N., Pasanisi, F., & Santarpia, L. (2024). Macrophage activation syndrome: a lifetrheatening complication in a 44 year old woman. Italian Journal of Medicine, 18(2). https://doi.org/10.4081/itjm.2024.1752